rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Quanterix Corporation

QTRX · Nasdaq

Health CareLife-science toolsNot moving yet

QTRX stood above a rising 150-day average in 12 of the last 52 weekly readings, and has been out of that trend for the last 33 weeks. It is 13.9% below that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 33
Industry in uptrend
52% +4 in 4 wk
Insider buys, 12 months
$592K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
128 (+9)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 12 of 52 weeks.

17 Apr – 16 Oct
26%41%57%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$2.8MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months3
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
William P. DonnellyDirectorbought72,245at $2.9313 Aug 2026filed 14 Aug 2026
William P. DonnellyDirectorbought27,155at $2.7512 Aug 2026filed 14 Aug 2026
Benjamin MeadowsChief Commercial Officerbought3,500at $2.7712 May 2026filed 12 Jun 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders128+9 on the quarter
New · exited38 · 29
Reported value$126.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20263,635,411$15.7M+357,816+10.9%
Blue Water Life Science Advisors, LPadded · filed 14 Aug 20263,474,202$15.0M+1,332,055+62.2%
First Eagle Investment Management, LLCadded · filed 5 Aug 20262,753,165$11.9M+1,453,078+111.8%
Portolan Capital Management, LLCreduced · filed 14 Aug 20261,899,308$8.2M-1,046,515−35.5%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,800,644$7.8M+16,031+0.9%
Lionhunter Capital Management, LLCnew · filed 13 Aug 20261,500,427$6.5M+1,500,427
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 20261,343,005$5.8M+1,258,873+1496.3%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20261,131,377$4.9M+136,613+13.7%
AMERIPRISE FINANCIAL INCreduced · filed 14 Aug 2026987,424$4.3M-2,554,950−72.1%
MARSHALL WACE, LLPadded · filed 13 Aug 2026973,872$4.2M+351,492+56.5%
31 Mar 2023 – 30 Jun 2026
108128147Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Michael Francis Miller Company insiderChief Technology Officer · last 15 Oct 20260 · 0
Ivana Magovcevic-Liebisch Company insiderDirector · last 2 Oct 20260 · 0
Scott Mendel Company insiderDirector · last 1 Oct 20260 · 0
William P. Donnelly Company insiderDirector · last 1 Oct 20264 · 0
James Edward Gute Jr. Company insiderChief Commercial Officer · last 15 Sep 20260 · 0
Jeffrey Thomas Elliott Company insiderDirector · last 19 Aug 20260 · 0
Jason F. Faessler Company insiderChief Financial Officer · last 15 Jul 20260 · 0
Goldman Myla Lai Company insiderDirector · last 8 Jul 20260 · 0
Vandana Sriram Company insiderChief Financial Officer · last 15 Jun 20261 · 0
Benjamin Meadows Company insiderChief Commercial Officer · last 12 May 20261 · 0
Everett Cunningham Company insiderPresident and CEO · last 19 Jan 20260 · 0
Masoud Toloue Company insiderPresident & CEO · last 15 Jan 20263 · 3

Same industry

OABI OmniAbLeading+65%
TXG 10x GenomicsLeading+60%
AVTR AvantorLeading+47%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+37%
MASS 908 DevicesLeading+31%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202546.8%
Operating profit marginFY 2025 · to 31 Dec 2025-90.4%
Free cash flow marginFY 2025 · to 31 Dec 2025-57.5%
Return on capital employedFY 2025 · to 31 Dec 2025-36.5%
Interest coverFY 2025 · to 31 Dec 2025-14.65×
Research spendFY 2025 · to 31 Dec 202525.9%
Share count trendFY 2025 · to 23 Feb 20260.4%
Cash and equivalentsFY 2025 · to 31 Dec 2025$29.8M
Free cash flowFY 2025 · to 31 Dec 2025−$79.8M

Analyst forecasts

No analyst forecasts yet.